<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762359</url>
  </required_header>
  <id_info>
    <org_study_id>AG-1749-CCT-351</org_study_id>
    <secondary_id>070494</secondary_id>
    <secondary_id>U1111-1113-9929</secondary_id>
    <secondary_id>R100125</secondary_id>
    <nct_id>NCT00762359</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers</brief_title>
  <official_title>A Study to Investigate the Preventive Effect of AG-1749 Against the Recurrence of Gastric And Duodenal Ulcers During Long-Term Treatment With Low Dose Aspirin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether lansoprazole, once daily (QD), compared to
      gefarnate, twice daily (BID), is effective in preventing the recurrence of gastric and
      duodenal ulcers in patients receiving long term treatment with low dosage aspirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Japan, low-dose aspirin is one of the commonly prescribed drugs for inhibiting thrombosis
      and thrombus formation after angina, myocardial infarction, ischemic cerebrovascular disease,
      coronary artery by-pass surgery and percutaneous transluminal coronary angioplasty in
      patients. While low-dose aspirin is effective in these cases, its use sometimes causes
      gastric and duodenal ulcers which can lead to gastrointestinal bleeding, and in worse cases
      may lead to death.

      The purpose of this study is to assess the efficacy of lansoprazole versus gefarnate in
      patients with a history of gastric or duodenal ulcers receiving daily low dose aspirin
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    AG-1749 superior to Gefarnate in ulcer prevention
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Gastric Ulcer and/or Duodenal Ulcer</measure>
    <time_frame>18 Months</time_frame>
    <description>The number of participants that developed gastric ulcer and/or duodenal ulcer at month 18 or final visit. Ulcers are defined as mucosal defect with white coating 3 mm or greater.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)</measure>
    <time_frame>Baseline and Month 3.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)</measure>
    <time_frame>Baseline and Month 6.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9)</measure>
    <time_frame>Baseline and Month 9.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)</measure>
    <time_frame>Baseline and Month 18.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)</measure>
    <time_frame>Baseline and Month 3.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)</measure>
    <time_frame>Baseline and Month 6.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9)</measure>
    <time_frame>Baseline and Month 9.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)</measure>
    <time_frame>Baseline and Month 18.</time_frame>
    <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Gastric or Duodenal Ulcer or Gastric or Duodenal Hemorrhagic Lesion (Upper Gastrointestinal Hemorrhage)</measure>
    <time_frame>18 Months</time_frame>
    <description>Number of participants with gastric or duodenal ulcer or gastric or duodenal hemorrhagic lesion (upper gastrointestinal hemorrhage) from baseline through month 18 or final visit. Ulcers are defined as mucosal defect with white coating 3 mm or greater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 3)</measure>
    <time_frame>Baseline and Month 3.</time_frame>
    <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 6)</measure>
    <time_frame>Baseline and Month 6.</time_frame>
    <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 9)</measure>
    <time_frame>Baseline and Month 9.</time_frame>
    <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 12)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 18)</measure>
    <time_frame>Baseline and Month 18.</time_frame>
    <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 3)</measure>
    <time_frame>Baseline and Month 3.</time_frame>
    <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 6)</measure>
    <time_frame>Baseline and Month 6.</time_frame>
    <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 9)</measure>
    <time_frame>Baseline and Month 9.</time_frame>
    <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 12)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 18)</measure>
    <time_frame>Baseline and Month 18.</time_frame>
    <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 3)</measure>
    <time_frame>Baseline and Month 3.</time_frame>
    <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 6)</measure>
    <time_frame>Baseline and Month 6.</time_frame>
    <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 9)</measure>
    <time_frame>Baseline and Month 9.</time_frame>
    <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 12)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 18)</measure>
    <time_frame>Baseline and Month 18.</time_frame>
    <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 3)</measure>
    <time_frame>Baseline and Month 3.</time_frame>
    <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 6)</measure>
    <time_frame>Baseline and Month 6.</time_frame>
    <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 9)</measure>
    <time_frame>Baseline and Month 9.</time_frame>
    <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 12)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 18)</measure>
    <time_frame>Baseline and Month 18.</time_frame>
    <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 3)</measure>
    <time_frame>Baseline and Month 3.</time_frame>
    <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 6)</measure>
    <time_frame>Baseline and Month 6.</time_frame>
    <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 9)</measure>
    <time_frame>Baseline and Month 9.</time_frame>
    <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 12)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 18)</measure>
    <time_frame>Baseline and Month 18.</time_frame>
    <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 3)</measure>
    <time_frame>Baseline and Month 3.</time_frame>
    <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 6)</measure>
    <time_frame>Baseline and Month 6.</time_frame>
    <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 9)</measure>
    <time_frame>Baseline and Month 9.</time_frame>
    <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 12)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 18)</measure>
    <time_frame>Baseline and Month 18.</time_frame>
    <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 3)</measure>
    <time_frame>Baseline and Month 3.</time_frame>
    <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 6)</measure>
    <time_frame>Baseline and Month 6.</time_frame>
    <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 9)</measure>
    <time_frame>Baseline and Month 9.</time_frame>
    <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 12)</measure>
    <time_frame>Baseline and Month 12.</time_frame>
    <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 18)</measure>
    <time_frame>Baseline and Month 18.</time_frame>
    <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>18 Months</time_frame>
    <description>Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug. A TEAE may also be a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Please see Other Adverse Events table below for TEAE listings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">461</enrollment>
  <condition>Stomach Ulcer</condition>
  <condition>Duodenal Ulcer</condition>
  <arm_group>
    <arm_group_label>Lansoprazole 15 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Gefarnate 50 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
    <arm_group_label>Lansoprazole 15 mg QD</arm_group_label>
    <other_name>AG-1749</other_name>
    <other_name>PREVACID®</other_name>
    <other_name>Takepron®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefarnate</intervention_name>
    <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
    <arm_group_label>Gefarnate 50 mg BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient was on low-dose aspirin treatment on the day when consent was obtained,
             and requires the long-term continuous treatment even after treatment with the
             investigational drug is started.

          -  The patient was confirmed to have a history of gastric ulcer or duodenal ulcer.

        Exclusion Criteria:

          -  Endoscopically confirmed gastric and/or duodenal ulcers on Day 1.

          -  Endoscopically confirmed active upper gastrointestinal hemorrhage on Day 1.

          -  Current or past history of aspirin-induced asthma or hypersensitivity to nonsteroidal
             anti-inflammatory drugs.

          -  Past or planned surgery affecting gastric acid secretion.

          -  Clinically significant hepatic or renal disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Matsudo-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yotsukaido-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Imabari-shi</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama-shi</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Onga-gun</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gifu-shi</city>
        <state>Gifu</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujioka-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashihiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kure-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asahikawa-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hakodate-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashiibaraki-gun</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hitachinaka-shi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inashiki-gun</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Namegata-shi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsuchiura-shi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yuuki-shi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hakusan-shi</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa-shi</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Komatsu-shi</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takamatsu-shi</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujisawa-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yamato-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokosuka-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kochi-shi</city>
        <state>Kochi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsusaka-shi</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shima-shi</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsu-shi</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ebino-shi</city>
        <state>Miyazaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki-shi</city>
        <state>Miyazaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Joetsu-shi</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niigata-shi</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beppu-shi</city>
        <state>Ooita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ooita-shi</city>
        <state>Ooita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ibaraki-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsubara-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takatsuki-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hanyuu-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ootsu-shi</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamada-shi</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunto-gun</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuke-shi</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hachioji-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiyose-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Higashitagawa-gun</city>
        <state>Yamagata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iwakuni-shi</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimonoseki-shi</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>February 3, 2011</results_first_submitted>
  <results_first_submitted_qc>April 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 10, 2011</results_first_posted>
  <last_update_submitted>February 1, 2012</last_update_submitted>
  <last_update_submitted_qc>February 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Curling Ulcer</keyword>
  <keyword>Gastric Ulcer</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Acetylsalicylic Acid</keyword>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Duodenal Ulcer</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Gefarnate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at sites in Japan from May 2007 to November 2008.</recruitment_details>
      <pre_assignment_details>Participants were enrolled in either lansoprazole, once daily (QD) or gefarnate, twice daily (BID) treatment groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lansoprazole 15 mg QD</title>
          <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
        </group>
        <group group_id="P2">
          <title>Gefarnate 50 mg BID</title>
          <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="235"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="167"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Institution closed</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Removal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lansoprazole 15 mg QD</title>
          <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
        </group>
        <group group_id="B2">
          <title>Gefarnate 50 mg BID</title>
          <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
            <count group_id="B2" value="235"/>
            <count group_id="B3" value="461"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 40 and 49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 50 and 59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 60 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 65 and 69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 70 and 79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=80 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="235"/>
                    <measurement group_id="B3" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Gastric Ulcer and/or Duodenal Ulcer</title>
        <description>The number of participants that developed gastric ulcer and/or duodenal ulcer at month 18 or final visit. Ulcers are defined as mucosal defect with white coating 3 mm or greater.</description>
        <time_frame>18 Months</time_frame>
        <population>Participants not taking investigational drug were not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gastric Ulcer and/or Duodenal Ulcer</title>
          <description>The number of participants that developed gastric ulcer and/or duodenal ulcer at month 18 or final visit. Ulcers are defined as mucosal defect with white coating 3 mm or greater.</description>
          <population>Participants not taking investigational drug were not included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.0989</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0425</ci_lower_limit>
            <ci_upper_limit>0.2300</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
        <time_frame>Baseline and Month 3.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.150" spread="0.904"/>
                    <measurement group_id="O2" value="0.460" spread="1.241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
        <time_frame>Baseline and Month 6.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.153" spread="1.172"/>
                    <measurement group_id="O2" value="0.530" spread="1.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
        <time_frame>Baseline and Month 9.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.149" spread="1.157"/>
                    <measurement group_id="O2" value="0.419" spread="1.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
        <time_frame>Baseline and Month 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.224" spread="1.112"/>
                    <measurement group_id="O2" value="0.205" spread="1.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0433</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
        <time_frame>Baseline and Month 18.</time_frame>
        <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Gastric Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the stomach, graded on a 5 point scale (0=normal; 1= erosion/hemorrhage in one area of the stomach and &lt;1 lesion; 2= erosion/hemorrhage in one area of the stomach with 2-5 lesions; 3= erosion/hemorrhage in two areas in the stomach/one area involves &gt;6 lesions; 4= erosion/hemorrhage appear in three or more areas in the stomach). Erosions are mucosal defect &lt; 3 mm. Ulcers are mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of gastric mucosal injury.</description>
          <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
        <time_frame>Baseline and Month 3.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 3)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.132" spread="0.552"/>
                    <measurement group_id="O2" value="0.228" spread="0.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
        <time_frame>Baseline and Month 6.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 6)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.165" spread="0.583"/>
                    <measurement group_id="O2" value="0.149" spread="0.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
        <time_frame>Baseline and Month 9.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 9)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.092" spread="0.542"/>
                    <measurement group_id="O2" value="0.216" spread="0.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
        <time_frame>Baseline and Month 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 12)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.254" spread="0.766"/>
                    <measurement group_id="O2" value="0.136" spread="0.409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)</title>
        <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
        <time_frame>Baseline and Month 18.</time_frame>
        <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Duodenal Mucosal Injury Assessed by Lanza Score (Partially Revised) (Month 18)</title>
          <description>The Lanza score (partially revised) attributes the severity of induced erosive mucosal injury in the duodenum, graded on a 4 point scale (0=normal; 1= erosion and hemorrhage are localized in one area of the duodenum and &lt; 1 lesion; 2= 2 to 5 lesions ; 3= &gt; 6 lesions). Erosions are defined as mucosal defect &lt; 3 mm. Ulcers are defined as mucosal defect with white coating ≥ 3 mm. Higher scores indicate greater severity of duodenal mucosal injury.</description>
          <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Gastric or Duodenal Ulcer or Gastric or Duodenal Hemorrhagic Lesion (Upper Gastrointestinal Hemorrhage)</title>
        <description>Number of participants with gastric or duodenal ulcer or gastric or duodenal hemorrhagic lesion (upper gastrointestinal hemorrhage) from baseline through month 18 or final visit. Ulcers are defined as mucosal defect with white coating 3 mm or greater.</description>
        <time_frame>18 Months</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gastric or Duodenal Ulcer or Gastric or Duodenal Hemorrhagic Lesion (Upper Gastrointestinal Hemorrhage)</title>
          <description>Number of participants with gastric or duodenal ulcer or gastric or duodenal hemorrhagic lesion (upper gastrointestinal hemorrhage) from baseline through month 18 or final visit. Ulcers are defined as mucosal defect with white coating 3 mm or greater.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 3)</title>
        <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 3.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 3)</title>
          <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.187"/>
                    <measurement group_id="O2" value="0.015" spread="0.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6148</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 6)</title>
        <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 6.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 6)</title>
          <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.025" spread="0.158"/>
                    <measurement group_id="O2" value="-0.030" spread="0.171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8050</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 9)</title>
        <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 9.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 9)</title>
          <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.027" spread="0.163"/>
                    <measurement group_id="O2" value="-0.023" spread="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8678</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 12)</title>
        <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 12)</title>
          <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.143"/>
                    <measurement group_id="O2" value="-0.071" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2688</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 18)</title>
        <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 18.</time_frame>
        <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Postprandial Pain Gastrointestinal Symptom (Month 18)</title>
          <description>Postprandial pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.333" spread="0.577"/>
                    <measurement group_id="O2" value="-1.000">No test was performed when the number of cases was 5 or less.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 3)</title>
        <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 3.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 3)</title>
          <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.307"/>
                    <measurement group_id="O2" value="0.026" spread="0.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7054</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 6)</title>
        <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 6.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 6)</title>
          <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.038" spread="0.192"/>
                    <measurement group_id="O2" value="-0.008" spread="0.261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3400</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 9)</title>
        <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 9.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 9)</title>
          <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.027" spread="0.211"/>
                    <measurement group_id="O2" value="-0.023" spread="0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8813</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 12)</title>
        <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 12)</title>
          <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.204"/>
                    <measurement group_id="O2" value="-0.071" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1862</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 18)</title>
        <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 18.</time_frame>
        <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hunger and Nighttime Pain Gastrointestinal Symptom (Month 18)</title>
          <description>Hunger and nighttime pain is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.333" spread="0.577"/>
                    <measurement group_id="O2" value="-1.000">No test was performed when the number of cases was 5 or less.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 3)</title>
        <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 3.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 3)</title>
          <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.315"/>
                    <measurement group_id="O2" value="-0.005" spread="0.312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8604</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 6)</title>
        <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 6.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 6)</title>
          <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.329"/>
                    <measurement group_id="O2" value="0.015" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5485</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 9)</title>
        <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 9.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 9)</title>
          <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.027" spread="0.368"/>
                    <measurement group_id="O2" value="-0.023" spread="0.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7382</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 12)</title>
        <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 12)</title>
          <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.143"/>
                    <measurement group_id="O2" value="-0.036" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7619</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 18)</title>
        <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 18.</time_frame>
        <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Enlarged Abdomen Gastrointestinal Symptom (Month 18)</title>
          <description>Feeling of enlarged abdomen is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No test was performed when the number of cases was 5 or less.</measurement>
                    <measurement group_id="O2" value="NA">No test was performed when the number of cases was 5 or less.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 3)</title>
        <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 3.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 3)</title>
          <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.025" spread="0.233"/>
                    <measurement group_id="O2" value="0.020" spread="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0204</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 6)</title>
        <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 6.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 6)</title>
          <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" spread="0.220"/>
                    <measurement group_id="O2" value="0.008" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0046</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 9)</title>
        <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 9.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 9)</title>
          <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.072" spread="0.260"/>
                    <measurement group_id="O2" value="0.012" spread="0.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0059</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 12)</title>
        <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 12)</title>
          <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.082" spread="0.277"/>
                    <measurement group_id="O2" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1229</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 18)</title>
        <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 18.</time_frame>
        <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Nausea Gastrointestinal Symptom (Month 18)</title>
          <description>Feeling of nausea is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No test was performed when the number of cases was 5 or less.</measurement>
                    <measurement group_id="O2" value="NA">No test was performed when the number of cases was 5 or less.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 3)</title>
        <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 3.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 3)</title>
          <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.064" spread="0.387"/>
                    <measurement group_id="O2" value="-0.005" spread="0.411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2694</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 6)</title>
        <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 6.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 6)</title>
          <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.089" spread="0.346"/>
                    <measurement group_id="O2" value="0.038" spread="0.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0141</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 9)</title>
        <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 9.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 9)</title>
          <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.063" spread="0.411"/>
                    <measurement group_id="O2" value="0.000" spread="0.376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3128</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 12)</title>
        <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 12)</title>
          <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.163" spread="0.373"/>
                    <measurement group_id="O2" value="-0.036" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1450</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 18)</title>
        <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 18.</time_frame>
        <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Feeling of Heartburn Gastrointestinal Symptom (Month 18)</title>
          <description>Feeling of heartburn is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No test was performed when the number of cases was 5 or less.</measurement>
                    <measurement group_id="O2" value="NA">No test was performed when the number of cases was 5 or less.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 3)</title>
        <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 3.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 3)</title>
          <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.254"/>
                    <measurement group_id="O2" value="0.010" spread="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6175</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 6)</title>
        <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 6.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 6)</title>
          <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.177"/>
                    <measurement group_id="O2" value="0.000" spread="0.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4496</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 9)</title>
        <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 9.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 9)</title>
          <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.190"/>
                    <measurement group_id="O2" value="0.000" spread="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4718</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 12)</title>
        <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 12)</title>
          <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" spread="0.204"/>
                    <measurement group_id="O2" value="-0.036" spread="0.189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4484</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 18)</title>
        <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 18.</time_frame>
        <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Anorexia Gastrointestinal Symptom (Month 18)</title>
          <description>Severity of anorexia is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.333" spread="0.577"/>
                    <measurement group_id="O2" value="NA">No test was performed when the number of cases was 5 or less.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 3)</title>
        <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 3.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 3)</title>
          <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.099"/>
                    <measurement group_id="O2" value="0.020" spread="0.286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2604</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 6)</title>
        <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 6.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 6)</title>
          <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.138"/>
                    <measurement group_id="O2" value="0.000" spread="0.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6818</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 9)</title>
        <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 9.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 9)</title>
          <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.009" spread="0.165"/>
                    <measurement group_id="O2" value="-0.012" spread="0.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9015</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 12)</title>
        <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 12.</time_frame>
        <population>Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 12)</title>
          <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.020" spread="0.143"/>
                    <measurement group_id="O2" value="0.000" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4497</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 18)</title>
        <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
        <time_frame>Baseline and Month 18.</time_frame>
        <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Severity of Hematemesis and Melena Gastrointestinal Symptom (Month 18)</title>
          <description>Severity of hematemesis and melena (blood stool, black stool, tarry stool) is graded on a 4 point scale (0=none; 1=mild; 2=moderate; 3=severe). Higher scores indicate greater severity of gastrointestinal symptom.</description>
          <population>No test was performed when the number of cases was 5 or less. Values are from the Full Analysis Set.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No test was performed when the number of cases was 5 or less.</measurement>
                    <measurement group_id="O2" value="NA">No test was performed when the number of cases was 5 or less.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug. A TEAE may also be a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Please see Other Adverse Events table below for TEAE listings.</description>
        <time_frame>18 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lansoprazole 15 mg QD</title>
            <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
          </group>
          <group group_id="O2">
            <title>Gefarnate 50 mg BID</title>
            <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug. A TEAE may also be a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Please see Other Adverse Events table below for TEAE listings.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="234"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event (Frequency ≥5%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse event related to the study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event related to the study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were summarized by onset date occurring on or after the first dose of double-blind study medication.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lansoprazole 15 mg QD</title>
          <description>Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.</description>
        </group>
        <group group_id="E2">
          <title>Gefarnate 50 mg BID</title>
          <description>Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Corneal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Alcoholic pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Small intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Pharyngeal cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="234"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="226"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="234"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The clinical trial contract states that information should never be disclosed without prior consent of the sponsor, although it does not specify the number of days during which disclosure of information is limited.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>On September 2008, the Efficacy and Safety Evaluation Committee recommended that this study be discontinued based on the interim analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sr. VP Clinical Science</name_or_title>
      <organization>Takeda Global Research and Development Center, Inc.</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

